SEGLENTIS Drug Patent Profile
✉ Email this page to a colleague
When do Seglentis patents expire, and when can generic versions of Seglentis launch?
Seglentis is a drug marketed by Kowa Pharms and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and five patent family members in thirty-five countries.
The generic ingredient in SEGLENTIS is celecoxib; tramadol hydrochloride. There are twenty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the celecoxib; tramadol hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Seglentis
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 19, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SEGLENTIS
International Patents: | 105 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SEGLENTIS |
What excipients (inactive ingredients) are in SEGLENTIS? | SEGLENTIS excipients list |
DailyMed Link: | SEGLENTIS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SEGLENTIS
Generic Entry Date for SEGLENTIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SEGLENTIS
Drug Class | Nonsteroidal Anti-inflammatory Drug Opioid Agonist |
Mechanism of Action | Cyclooxygenase Inhibitors Full Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for SEGLENTIS
US Patents and Regulatory Information for SEGLENTIS
SEGLENTIS is protected by seven US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEGLENTIS is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SEGLENTIS
Co-crystals of tramadol and coxibis
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical compositions of co-crystals of tramadol and coxibs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting SEGLENTIS
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SEGLENTIS
When does loss-of-exclusivity occur for SEGLENTIS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 9008
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 09304235
Estimated Expiration: ⤷ Try a Trial
Patent: 10306168
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0920358
Estimated Expiration: ⤷ Try a Trial
Patent: 2012005011
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 37754
Estimated Expiration: ⤷ Try a Trial
Patent: 71665
Estimated Expiration: ⤷ Try a Trial
China
Patent: 2186465
Estimated Expiration: ⤷ Try a Trial
Patent: 2573825
Estimated Expiration: ⤷ Try a Trial
Patent: 4817501
Estimated Expiration: ⤷ Try a Trial
Patent: 4844513
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 11248
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0130316
Estimated Expiration: ⤷ Try a Trial
Patent: 0161526
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 13956
Estimated Expiration: ⤷ Try a Trial
Patent: 18374
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 49238
Estimated Expiration: ⤷ Try a Trial
Patent: 88169
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 12011734
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 77215
Estimated Expiration: ⤷ Try a Trial
Patent: 49238
Estimated Expiration: ⤷ Try a Trial
Patent: 88169
Estimated Expiration: ⤷ Try a Trial
Patent: 86432
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 73380
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 30976
Estimated Expiration: ⤷ Try a Trial
India
Patent: 35DEN2012
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 1785
Estimated Expiration: ⤷ Try a Trial
Patent: 8256
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 99564
Estimated Expiration: ⤷ Try a Trial
Patent: 45830
Estimated Expiration: ⤷ Try a Trial
Patent: 12505847
Estimated Expiration: ⤷ Try a Trial
Patent: 13507402
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 49238
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 6285
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 6318
Estimated Expiration: ⤷ Try a Trial
Patent: 11003612
Estimated Expiration: ⤷ Try a Trial
Patent: 12003050
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 742
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 1873
Estimated Expiration: ⤷ Try a Trial
Patent: 8353
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 49238
Estimated Expiration: ⤷ Try a Trial
Patent: 88169
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 49238
Estimated Expiration: ⤷ Try a Trial
Patent: 88169
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 47830
Estimated Expiration: ⤷ Try a Trial
Patent: 99717
Estimated Expiration: ⤷ Try a Trial
Patent: 11119608
Estimated Expiration: ⤷ Try a Trial
Patent: 12120088
Estimated Expiration: ⤷ Try a Trial
San Marino
Patent: 01300048
Estimated Expiration: ⤷ Try a Trial
Patent: 01600439
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 8835
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 49238
Estimated Expiration: ⤷ Try a Trial
Patent: 88169
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1102762
Estimated Expiration: ⤷ Try a Trial
Patent: 1201892
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1471585
Estimated Expiration: ⤷ Try a Trial
Patent: 1679400
Estimated Expiration: ⤷ Try a Trial
Patent: 110069860
Estimated Expiration: ⤷ Try a Trial
Patent: 120099212
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 02112
Estimated Expiration: ⤷ Try a Trial
Patent: 03962
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 41630
Estimated Expiration: ⤷ Try a Trial
Patent: 1116273
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 12000075
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 9534
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SEGLENTIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2012505847 | ⤷ Try a Trial | |
Russian Federation | 2012120088 | СОКРИСТАЛЛЫ ТРАМАДОЛА И КОКСИБОВ | ⤷ Try a Trial |
Taiwan | I508722 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEGLENTIS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0731795 | 10075033 | Germany | ⤷ Try a Trial | PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |